PMGC Holdings ELAB
NASDAQ ELAB
$4.70 +0.08 (+1.72%)
As of: Sep 10, 2026 · 12:55 PM EDT

PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026)

PMGC Holdings' (ELAB) quarterly Non-Current Assets came in at $15.7 million in Q2 2026, up 659.01% year-over-year from $2.1 million in Q2 2025, and up 63.08% quarter-over-quarter from $9.6 million in Q1 2026.

Analysis

PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed Non-Current Assets across 5 years of filings, most recently posting $15.7 million for Q2 2026.

  • In Q2 2026, Non-Current Assets rose 659.01% year-over-year to $15.7 million; the TTM figure through Jun 2026 stood at $15.7 million (up 54.66% YoY), while the FY2025 annual figure was $6.0 million, up 103.84% from the prior year.
  • Non-Current Assets came in at $15.7 million for Q2 2026 at PMGC Holdings, up from $9.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $306.4 million in Q3 2023 to a low of $270474.0 in Q4 2023.
  • Average Non-Current Assets over 5 years is $27.5 million, with a median of $3.0 million recorded in 2024.
  • The largest YoY upside for Non-Current Assets was 987.78% in 2024 against a maximum downside of 99.03% in 2024.
  • Over 5 years, Non-Current Assets stood at $340861.0 in 2022, then slipped by 20.65% to $270474.0 in 2023, then jumped by 987.78% to $2.9 million in 2024, then surged by 103.84% to $6.0 million in 2025, then jumped by 162.31% to $15.7 million in 2026.
  • Per Business Quant data, the three most recent Non-Current Assets figures were $15.7 million in Q2 2026, $9.6 million in Q1 2026, and $6.0 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 206.09 Bn 192.10 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 179.75 Bn 176.57 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 131.11 Bn 123.26 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.77 Bn 73.78 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.45 Bn 55.27 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.60 Bn 48.46 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.36 Bn 30.06 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.72 Bn 30.44 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.09 Bn 29.09 Bn 1.16 Mn 564.41 Mn
10 PMGC Holdings 2.29 Mn -16.50 Mn 385,691.00 15.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.73 Mn
Mar 31, 2026 9.65 Mn
Dec 31, 2025 6.00 Mn
Sep 30, 2025 5.17 Mn
Jun 30, 2025 2.07 Mn
Mar 31, 2025 2.07 Mn
Dec 31, 2024 2.94 Mn
Sep 30, 2024 2.98 Mn
Jun 30, 2024 3.05 Mn
Mar 31, 2024 1.09 Mn
Dec 31, 2023 270,474.00
Sep 30, 2023 306.39 Mn
Dec 31, 2022 340,861.00